March 2026 Quarterly Activity Report and Appendix 4C
Filed with ASX · · 11 pages · English
Story so far
Earlier from Racura Oncology
- Racura presents MYC silencing data at AACR 2026
- First Patient Recruited to HARNESS-1 Lung Cancer Trial
- First Patient Dosed Safely with RC220 in Hong Kong
- Racura HARNESS-1 Trial Receives Governance Approval
- Appendix 4D & Half-Year Financial Statements
Later from Racura Oncology
- (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
- CPACS Trial Cleared to Escalate to Next RC220 Dose Level
- Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
- Racura Enters Underwriting Agreement for Options
- Emerging Companies Specialist Invests in Racura
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology